The pilot study on evaluation of EPA+DHA therapy with Endo-PAT

The pilot study on evaluation of EPA+DHA therapy with Endo-PAT - The pilot study on evaluation of EPA+DHA therapy with Endo-PAT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039168

Enrollment

Registered

2020-01-15

Start date

2017-09-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cases with reduced vascular endothelial function

Interventions

Administer EPA + DHA (Rotriga) 4g / day for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) With dyslipidemia, indicated for taking EPA + DHA. 2) RHI value by Endo-PAT test is less than 1.67. 3) Age at the time of consent is 20 years or older. 4) Informed consent has been obtained from the person in question regarding participation in the research.

Exclusion criteria

Exclusion criteria: Does not meet eligibility criteria

Design outcomes

Primary

Measure	Time frame
Change in RHI value 12 weeks after starting EPA + DHA administration by Endo-PAT test	—

Countries

Japan

Contacts

Public ContactTobita Hiroshi

Shimane University School of Medicine Hepatology

ht1020@med.shimane-u.ac.jp0853-20-2190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026